



Sudan Cardio

Welcome Message

It is my pleasure to announce to you the Fourth International Conference of Sudan Heart Society (SHS). This year we equally have the honor to jointly hold the first Pan African Cardiac imaging conference. We are delighted to arrange this on behalf of PASCAR. I have the pleasure to invite you all to join us in Khartoum in the period from 26th January 2015 to 31st January 2016. This year we changed venue but we will remain on the banks of the River Nile in the prestigious Friendship Hall. On these two announced ventures we expect the contribution of thirty three international faculties from Europe, United State, Africa and the Arab World. We hope our guests will include expert participants in a variety of disciplines from all over the world. We hope that the meeting will highlight and discuss the outcomes of recently published and announced large and land mark cardiology clinical trials. Throughout the conference sessions this will remain in though. For the first time in Africa Dr. Subahi as vice president of PASCAR, has assembled a faculty of world expert in cardiac imaging. During the imaging conference, either in separate sessions or in parallel sessions, our guest faculty will explore and navigate through the rapidly evolving and advancing world of cardiac imaging. Active workshops on the different modalities of cardiac imaging will take place prior to the conference. For the purpose of continuous education, the conference activities are structured to include three dedicated workshops including: Cardiac Catheterization/Intervention course, Echocardiography workshop and CT, MRI workshop. Registration for the conference and workshops will be available on line through our website and through mobile phone applications. The conference scientific program, dates and details of symposia and program evaluation forms will be available together with the application form. Khartoum is a nice and peaceful city where the two Niles meet. Their meeting point is a short distance from the conference venue. Khartoum enjoys cool but never cold clear skies in Januarys. It is a good time to visit Khartoum.

On behalf of my colleagues in the Conference Management Committee, I would like to welcome our speakers, delegates and guests.

We hope that you will give us the opportunity to welcome you in Khartoum and truly express our Sudanese people's well known warmth and Hospitality.

DR. A.R Ziada
President SHS



Welcome Message

Welcome to the fascinating city of Khartoum to join us for PASCAR 1st cardiac Imaging Conference. This is the first scientific event in Africa to focus on echocardiography and other imaging modalities. We aim to create a forum where both clinicians and imaging experts can discuss their clinical findings and experience.

The conference will focus on the clinical scenario demonstrating how imaging modalities may affect the clinical decision making and outcome.

An educational track will run throughout the conference featuring several specially designed sessions. Our preconference workshops include TEE, Basic TTE, CCT and CMR.

However, our Imaging conference (PASCAR Imaging) is more than just education and science. It is also a unique opportunity to meet international renowned experts in cardiovascular imaging, to exchange ideas and projects with colleagues who share the same clinical and scientific interest coming from all over the world.

Khartoum, the capital of Sudan is famous for its culture, history and special Sudanese charm, so we trust you will make the most of your time here.

Dr.Saad Subahi FRCP

Vice President (North) PASCAR



List of SHS doctors participating in the C3 this year June 2015:

No	Name	Professional Status	Institute
1	Abdelrahman Ziadah	President SHS	Fidail Hospital
2	Dr Elsadig M A Askar	General Secretary SHS	The National Cardiac Centre at Elshaab Hospital
3	Saad Subahi	Vice president (North) PASCAR	Sahiroun Hospital
4	Dr Salah M I Mohamed (Elbasha)	Consultant Interventional Cardiologist	The National Cardiac Centre at Elshaab Hospital
5	Awad Abdallah	Consultant Interventional Cardiologist	The National Cardiac Centre at Elshaab Hospital
6	Yagoub Marzoug	Consultant Interventional Cardiologist	The National Cardiac Centre at Elshaab Hospital
7	Dr Ahmed A A Suliman	Consultant Interventional Cardiologist	The National Cardiac Centre at Elshaab Hospital
8	Dr Osman Elsayed	Consultant Interventional Cardiologist	Ahmed Gasim Hospital
9	Dr Huda Hamid	Consultant Cardiologist	Ahmed Gasim Hospital
10	Dr Eltayeb M Elriba'a	Consultant Interventional Cardiologist	The National Cardiac Centre at Elshaab Hospital
11	Dr Yassein M Mohamed	Consultant Interventional Cardiologist	Ahmed Gasim Hospital
12	Anas Babikir	Consultant Cardiologist	Royal Care International Hospital



13	Dr Mohamed Ibrahim	Consultant Cardiologist	The National Cardiac Centre at Elshaab Hospital
14	Dr Murtada Hamza	Consultant Cardiologist	The National Cardiac Centre at Elshaab Hospital
15	Dr Omer Mohammed I	Consultant Cardiologist	The National Cardiac Centre at Elshaab Hospital
16	Dr Lway I M Ibrahim	Consultant Cardiologist	The National Cardiac Centre at Elshaab Hospital
17	Dr Magid Gameel	Consultant Interventional Cardiologist	Sudan Cardiac Centre
18	Dr Elbagir Abdelrahman	Consultant Interventional Cardiologist	Sudan Cardiac Centre
19	Dr Sahar Elfadil	Consultant Cardiologist	Sudan Cardiac Centre
20	Dr Noureldin Mohamed M A E	Cardiac Fellow	The National Cardiac Centre at Elshaab Hospital
21	Dr Mustafa I Ali M	Cardiac Fellow	The National Cardiac Centre at Elshaab Hospital
22	Dr Murtada M Mohammed A A	Cardiac Fellow	The National Cardiac Centre at Elshaab Hospital
23	Dr Khadija Salih	Consultant Cardiologist	Ahmed Gasim Hospital
24	Dr Hagir Elturabi	Cardiac fellow	Sudan Cardiac Centre
25	Nasreen Ahmed	Cardiac fellow	Sudan Cardiac Centre



Organizing Committee:



Chairperson: Saad Subahi



Abdelrahman Ziada



Elsadig Askar



Awad Abdullah



Sahar Alfadel



Nouraldin M.Attalsayed



Nesrin Elgasim



Hajer M. Khalid



Azza M.Omer

Secretarial Work



Rodab Satti



AMICOR

Bisoprolol fumarate

The highly recommended selective beta blocker.

AMICOR is beneficial to manage:

- 1- Hypertension.
- 2- Coronary heart disease (Arrhythmias).
- 3- myocardial infarction.
- 4- Ischemic heart disease.
- 5- As co-medicine in congestive heart failure.



It can also be used as preventive treatment before and primary after heart attack.



AMICOR
has a good
safety profile.

AMICOR as high quality product at an affordable price improves patient's compliance, which is a corner stone in cardiovascular diseases management.



AMICOR offers a versatility of dosage,

It is available as :

5 mg and 10 mg
for dosage, interactions and side effects
please see the inserted leaflet.



2.5 mg
2.5/6.25mg
5 mg
5 / 6.25 mg
10 mg
10 / 6.25mg




AMIPHARMA

Cardex[®]

Bisoprolol Fumarate

The Edge Of Life



 **Cardex[®]**
Bisoprolol Fumarate

Indicated and supported by guidelines in a wide range of cases alone or on top of other managements.

 **Cardex[®]**
Bisoprolol Fumarate

Effective BP Control compared to atenolol.

 **Cardex[®]**
Bisoprolol Fumarate

24 hrs Full day blood pressure optimization.

 **Cardex[®]**
Bisoprolol Fumarate

Markedly improves the clinical symptoms in 97.8% of angina patients.

 **Cardex[®]**
Bisoprolol Fumarate

Provide 40% mortality reduction post MI.

 **Cardex[®]**
Bisoprolol Fumarate

Significantly reduces cardiac death and myocardial infarction in high risk patients.

 **Cardex[®]**
Bisoprolol Fumarate

Is proven to provide lower mortality rates for CHF patients.




 **Cardex[®]**
Bisoprolol Fumarate

Proven anti arrhythmic effect.




 **tabuk**
pharmaceuticals
24 - 25 / 31 / 18 Block 5
Industrial Area , Khartoum North
PO-Box : 13537
Tel : +249 185 335774
Fax : +249 185 342886



Workshop Program

Time	Tuesday 26/1/2016 Police Club	
09:30 - 17:30	Transesophageal Echocardiography Workshop Programme	Presenter
Faculty	M. Dr.A.Salustri J.Kasprzak M.Elbur S.Subahi	
09:30 - 11:00	lectures	
09:30 - 09:45	Clinical applications	A.Salustri
09:45 - 10:00	Preparation and potential complications	M.Elbour
10:00 - 10:15	Instrumentation	J.Kasprzak
10:15 - 11:00	Image orientation and specific views	A.Salustri
11:00 - 11:30	 Coffee Break	
11:30 - 13:00	Case demonstration (live transmission)	J.Kasprzak
13:00 - 14:00	 Lunch	
14:00 - 15:30	Recorded cases (1)	A.Salustri J.Kasprzak M.Elbour S.Subahi
15:30 - 15:45	 Coffee Break	
15:45 - 17:30	Recorded cases (2)	A.Salustri J.Kasprzak M.Elbour S.Subahi



Time	Wednesday 27/1/2016 Police Club	
09:30 - 17:30	CT/CMR Workshop Programme	Presenter
Faculty	R.Mohiaddin (UK) A.Elsaileek (KSA) S.Moosa (SA)	
09:30 - 11:00	lectures	
09:30 - 09:45	Introduction	A.Alsaileek
09:45 - 10:00	Technical aspects	A.Alsaileek
10:00 - 10:15	Patient preparation and selection	A.Alsaileek
10:15 - 10:30	Limitations and safety issues	A.Alsaileek
10:30 - 10:45	Anatomy in cardiac CT	A.Alsaileek
11:00 - 11:30	 Coffee Break	
11:30 - 12:15	CCT : Clinical applications	A.Alsaileek
12:15 - 13:00	CMR topic : Current clinical applications of MR in cardiology	R.Mohiaddin
13:00 - 14:00	 Lunch	
14:00 - 15:30	Recorded cases CCT /CMR	A.Alsaileek R.Mohiaddin S.Moosa
15:30 - 16:00	 Coffee Break	
16:00 - 17:30	Recorded cases CCT /CMR	A.Alsaileek R.Mohiaddin S.Moosa

LOTENSE

Lotense[®]
Amlodipine Besylate

Has Effective 24-hour control and protection of BP and ischemia with a convenient single daily dose.

Lotense[®]
Amlodipine Besylate

Has No negative effect on heart rate and cardiac conduction.

Lotense[®]
Amlodipine Besylate

Does not adversely affect renal function.

Lotense[®]
Amlodipine Besylate

Is well-tolerated with very low discontinuation rate.

Lotense[®]
Amlodipine Besylate

Provided in distinctive capsule form.

Lotense[®]
Amlodipine Besylate


Standard Quality and trusted results.

The Reliable Therapeutic Strategy For Balancing High Blood Pressure



AMISTATIN

- Amistatin is Atrovastatin, used to manage hypercholesterolemia and for plaque stabilization



- Amistatin lowers the risk of heart attack in patients at high risk such as elderly, smokers, hypertensive, low HDL, or diabetics

- Amipharma offers high products quality at an affordable price that would improve patients compliance; a major obstacle in the management of hypercholesterolemia.



- Amistatin is available in film coated tablet of 20 mg and 40 mg as Atrovastatin calcium.



AMIPHARMA

CANDESTAN

Candesartan Cilexetil

- Candestan is candesartan cilexetil, a known selective angiotensin receptor antagonist (ARB), with high efficacy in managing hypertension and heart failure.



- Candestan is well tolerated by most patients even in the presence of concomitant diseases as diabetes, asthma, and kidney problems.

- Candestan once daily dosage coupled with its affordable prices, boosts patients compliance.
- Candestan offers a variety of strengths to manage diverse patients of 8 mg, 16 mg, 32 mg.








- And 16 /12.5 mg hydrochlorothiazide as Candestan Plus








AMIPHARMA



Scientific Program

Time	Thursday 28/1/2016
09:00 - 10:30	Echo (1) Basics of cardiac assessment
Chairpersons	M. Elbur Y.Abdelhey
09:00 - 09:22	 A.Salustri (UAE) Quantitation of left ventricular dimensions and function
09:22 - 09:44	 J.Kasprzak (Poland) Quantitation of right ventricular dimensions and function
09:44 - 10:06	 A.Salustri (UAE) Assessment of diastolic function
10:06 - 10:30	 J.Kasprzak (Poland) Left and right atrium : size and function
10:30 - 11:00	 Coffee break

Pan-African Society of Cardiology (PASCAR)
 First Cardiac Imaging Conference
 Sudan Heart Society (SHS) Fourth International Conference

Time	Thursday 28/1/2016
11:00 - 12:30	CCT 1
Chairpersons	J.Buithieu A.Sulaiman
11:00 - 11:22	 R.Murphy (Ireland) CCT :The first 10 years
11:22 - 11:44	 A.Saileek (Saudi Arabia) Cardiac CT in acute chest pain
11:44 - 12:06	 J.Buithieu (Canada) 3D echocardiography :Lessons learned from Cardiac CTA
12:06 - 12:30	 D.Ropers (Germany) Close to 25 years of experience: Calcium detection for risk prediction
12:30 - 14:00	 Lunch break



Time

Thursday 28/1/2016

14:00 - 15:30

Echo (2) Valves diseases

Chairpersons

J.Kasprzak
S.Alfadel

14:00 - 14:22



J.Kasprzak (Poland)
Grading aortic stenosis: tips and tricks

14:22 - 14:44



R.Murphy (Ireland)
Mitral regurgitation :primary and secondary

14:44 - 15:06



A.Salustri (UAE)
Assessment of tricuspid regurgitation

15:06 - 15:30







R.Murphy (Ireland)
Mitral stenosis : grading stenosis severity

15:30 - 16:00



Coffee break

Time	Thursday 28/1/2016
16:00 - 17:06	CMR 1
Chairpersons	D.Ropers S.Moosa
16:00 - 16:22	 A.Saileek (Saudi Arabia) Introduction to cardiac MRI (CMR)
16:22 - 16:44	 R.Mohiaddin (UK) CMR assessment of myocardial ischaemia and viability
16:44 - 17:06	 S.Moosa (South Africa) CMR evaluation of congenital heart disease
17:06	 R.Mohiaddin (UK) Role of CMR in the assessment of cardiac masses



Time

Friday 29/1/2016

08:30 - 10:00

Echo (3) Advanced echo techniques

Chairpersons

A.Salustri
H.Hamid

08:30 - 08:52



J.Smallhorn (Canada)
3D echo (1) practical applications

08:52 - 09:14



J.Buithieu (Canada)
Role of echocardiography in interventional cardiology: road map to the future

09:14 - 09:36



Z.Yousef (UK)
Role of imaging in cardiac device selection

09:36 - 10:00



J.Smallhorn (Canada)
3D echo (2) congenital heart disease

10:00 - 10:30



Coffee break

Pan-African Society of Cardiology (PASCAR)
 First Cardiac Imaging Conference
 Sudan Heart Society (SHS) Fourth International Conference

Time	Friday 29/1/2016
10:30 - 12:00	CCT (2) / Neuclear (1)
Chairpersons	A.Saileek R.Murphy
10:30 - 10:52	 A.Saileek (Saudi Arabia) Cardiac CT in valvular heart Disease
10:52 - 11:14	 D.Ropers (Germany) Functional assessment of stenosis severity in cardiac CT: Update in CT perfusion imaging and FFR-CT.
11:14 - 11:36	 L.Gerecke (Germany) Nuclear (1) Nuclear cardiovascular imaging techniques . review
11:36 - 12:00	 D.Ropers (Germany) CT angiography for the definition of coronary artery anomalies.
12:00 - 13:30	 Lunch break



Time

Friday 29/1/2016

13:30 - 15:00

CMR (2) /CCT / Neuclear

Chairpersons

R.Mohiaddin
L.Gercke

13:30 - 13:52



R.Mohiaddin (UK)

The added value of CMR in valvular heart disease

13:52 - 14:14



S.Mousa (South Africa)

CMR in non-ischaemic cardiomyopathies

14:14 - 14:36



A.Saileek (Saudi Arabia)

Cardiac CT after coronary intervention (PCI and CABG)

14:36 - 15:00



L.Gerecke (Germany)

Neuclear (2) practical applications

15:00 - 15:30



Coffee break

TIME 2 DO MORE in Diabetes

SURVEY: Background & Methodology



RATIONALE AND OBJECTIVES

Worldwide, more than 382 million people have diabetes, with one person dying from the disease every six seconds¹. The number of people with diabetes is increasing in every country across the globe, mainly due to rapid urbanization, changes in diet and increasingly sedentary lifestyles^{1,2}. Type 2 diabetes mellitus (T2DM) comprises 90 percent of all cases of diabetes³.

Despite these shocking statistics, 42 percent of people with T2DM who are treated do not reach their blood sugar goals, putting them at risk of organ and tissue damage, kidney disease, blindness, amputations and even death^{4,5}.

Time 2 Do More in Diabetes™ is a global survey of physicians and people with T2DM, conducted by Novartis Pharma AG in collaboration with leading medical experts, Dr. David Strain, Royal Devon & Exeter Hospital, UK and Prof. Matthias Blüher, University Hospital Leipzig, Germany. The survey examined the reasons why many people with T2DM do not reach blood sugar goals. Novartis is working with diabetes experts to analyze these findings and better understand awareness, attitudes and behaviors of physicians and people with T2DM in an effort to identify ways to improve the management of the disease.

AREAS OF FOCUS



- The survey investigated the perceptions of physicians and people with T2DM, related to⁶:
 - The consultation at the time of diagnosis and the topics discussed, including lifestyle changes (diet and exercise) and potential complications of the disease
 - Follow-up consultations
 - Attitudes towards potential disease complications
 - Disease management and the likelihood of achieving blood sugar goals with appropriate interventions
 - Treatment approaches

METHODOLOGY



- The survey was conducted via a 20 minute online questionnaire in six countries (U.S., UK, Spain, India, Japan and Brazil)⁶. The survey enrolled random participants from extensive panels of physicians and people with T2DM⁶
- The sample comprised 652 adults with T2DM and 337 treating physicians (264 general practitioners (GPs) and 73 specialists)⁶
 - The physicians surveyed spent at least 70 percent of their time attending patients (>50 patients per month for GPs and >100 patients per month for specialists)⁶

References


1. International Diabetes Federation. IDF Diabetes Atlas sixth edition, 2013. <http://www.idf.org/diabetesatlas/introduction>. Accessed November 14, 2013.
2. Hu F. Globalization of diabetes. *Diabetes Care* 2011;34(6):1249-1257.
3. International Diabetes Federation. Types of diabetes. <http://www.idf.org/types-diabetes>. Accessed October 29, 2013.
4. Brown JB et al. Secondary failure of metformin monotherapy in clinical practice. *Diabetes Care* 2010;33(3):501-50.
5. World Health Organization. Diabetes Fact Sheet No312. Available at: <http://www.who.int/mediacentre/factsheets/fs312/en/index.html>. Accessed October 29, 2013.
6. Time 2 Do More Survey. Novartis data on file 2013.

TIME 2 Do MORE IN DIABETES™

Worldwide, more than **382 million** people have diabetes, with **ONE PERSON DYING** from the disease every **SIX SECONDS**!

Despite these shocking statistics **42% OF PEOPLE WITH TYPE 2 DIABETES who are treated DO NOT REACH BLOOD SUGAR GOALS***

Novartis Pharma AG partnered with leading medical experts to conduct a global survey of 337 physicians and 652 people with type 2 diabetes mellitus (T2DM) to examine the main reasons why people with type 2 diabetes do not reach blood sugar goals.^{3,4*}



For more information on this survey and T2DM, please contact sandra.waite@novartis.com

Time 2 Do More In Diabetes™ was a global survey of physicians and people with type 2 diabetes, conducted by Novartis Pharma AG in collaboration with Dr. David Strain, Royal Devon & Exeter Hospital, UK and Prof. Matthias Blüher, University Hospital Leipzig, Germany.

*The survey was fielded in the U.S., UK, Japan, Brazil, India and Spain

**Physicians were asked to make their assessment based on an average 50 year old person with type 2 diabetes

REFERENCES

- International Diabetes Federation. IDF Diabetes Atlas sixth edition, 2013. <http://www.idf.org/diabetesatlas/introduction>. Accessed November 14, 2013.
- Brown JB et al. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33(3):601-60.
- Strain WD et al. Time 2 Do More. Addressing Clinical Inertia in the Management of Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice 2014. DOI: dx.doi.org/10.1016/j.diabres.2014.05.005
- Time 2 Do More in Diabetes survey. Novartis data on file 2013.

Time	Friday 29/1/2016
15:30 - 17:00	Echo (4) General
Chairpersons	K.Eloumda M.Jamil
15:30 - 15:52	 M.Elbur (UAE) Cardiac masses
15:52 - 16:14	 J.Buithieu (Canada) Basic Effective Echocardiography :Thinking in 3D
16:14 - 16:36	 A.Sulaiman (Sudan) Imaging In infective endocarditis
16:36 - 16:50	 D.Ropers(Germany) Multimodality imaging : case presentation
16:50 - 17:00	 S.Subahi (Sudan) Closing remarks



Time

Saturday 30/1/2016

08:30 - 10:30

Electrophysiology

Chairpersons

Mervat Aboalmaati
Albagir Albasheer

08:30 - 08:50



Zaheer Yousof (UK)
Heart Failure Device Therapy. Credibility.
Evidence based approach

08:50 - 09:10



Noel Boyle (USA)
A focus on Sudden Death in Sports

09:10 - 09:30

Mervat Aboalmaati
Management of asymptomatic pre-exci-
tation syndromes

09:30 - 09:50



Noel Boyle (USA)
Mnagement of non-ischaemic Ventricular
Tachyarrythmias





09:50 - 10:05

Discussion

10:05 - 10:30



Coffee Break

Time	Saturday 30/1/2016
10:30 - 11:50	Valvular Heart Disease (1)
Chairpersons	Christin Yoko Abdelbagi Sidahmad
10:30 - 10:50	 Ian Adata (Canada) New Therapies for Pulmonary Hypertension
10:50 - 11:10	 Mohammad Otaibi (Saudi Arabia) Mitra-clip where does it stand ?
11:10 - 11:30	To be announced
11:30 - 11:50	 Mrs. Kostantina MASOORA (UK) Challenges in the evaluation and management of Tricuspid valve disease
11:50 - 12:10	Discussion
12:10 - 13:10	 Lunch & Prayers



Time

Saturday 30/1/2016

10:30 - 11:50

Coronary Artery Disease: 1

Chairpersons

Amir Zaini
Salah Albash

10:30 - 10:50



Saddig Asker (Sudan)

The plague vulnerability/ plague stabilization

10:50 - 11:10



Moh Rosli (Malaysia)

Left main, Proximal/osteal LAD, What strategies ?

11:10 - 11:30



R.K.Jain (India)

Cardiogenic Shock Rules of engagement

11:30 - 11:50



Amir Zaini (Saudi Arabia)

Use of Antiplatelet therapy. What, when, how long

11:50 - 12:10

Discussion

12:10 - 13:10



Lunch & Prayers

Pan-African Society of Cardiology (PASCAR)
 First Cardiac Imaging Conference
 Sudan Heart Society (SHS) Fourth International Conference

Time	Saturday 30/1/2016
13:10-14:30	Heart Failure 2
Chairpersons	Zaheer Yousif Ahmad Ali Suleiman
13:10 - 13:30	 Zaheer Yousof (UK) Emergency Room Management of Acute Heart Failure
13:30 - 13:50	 Karen Sliwa (South Africa) Peripartum Heart Failure
13:50 - 14:10	 Anwar Gilani (Saudi Arabai) Premature Ventricular Beats Induced Cardio-myopathy
14:10 - 14:30	 Karen Sliwa (South Africa) Risk assessment of pregnancy in women with structural heart disease
14:30 - 14:50	Discussion
14:50 - 15:20	 Coffee break



Time	Saturday 30/1/2016
13:10-14:30	Thromboembolic Disease2
Chairpersons	Allaaldin Yousif Altayed Alobaid
13:10 - 13:30	 Fakhher Fathi (USA) Cather based treatment of Acute Pulmonary Embolism.
13:30 - 13:50	 Bhaskar Roa (India) Management of Chronic Pulmonary Embolism
13:50 - 14:10	 Fakhher Fathi (USA) IV Filter in management of Thromboembolism
14:10-14:30	 Osman Alhaj (UK) Marfan And The Heart
14:30 - 14:50	Discussion
14:50 - 15:20	 Coffee break

Pan-African Society of Cardiology (PASCAR)
First Cardiac Imaging Conference
Sudan Heart Society (SHS) Fourth International Conference

Time	Saturday 30/1/2016
15:20-17:00	Surgery/Paediatrics
Chairpersons	Elrasheed Omar Abdelbaset
15:20 - 15:40	 Christin Yoko (Kenya) EmergencyCathLabmanagementinchildren.
15:40 - 16:00	 Oliver Jejaden (France) Surgical approach to management of Mi- tral Valve Regurgitation
16:00 - 16:20	 Elrasheed Omer (Sudan) Management of Aortic Aneurysm
16:20 - 16:40	 Bhaskar Rao (India) Pre and Peri operative predictors of graft failure.
16:40 - 17:00	Discussion



Time

Saturday 30/1/2016

15:20-17:00

Coronary Artery Disease (1)

Chairpersons

Salah Abosin
Alrashee Saad

15:20 - 15:40



R.K.Jain (India)

Haemodynamic Support in High Risk PCI
and Cardiogenic Shock.

15:40 - 16:00



Anjela Hoye (UK)

Role of FFR in Coronary Artery Disease

16:00 - 16:20





Ahmad Alsayed

Local experience in management of Aortic
Aneurysm






16:40 - 17:00



Discussion

Pan-African Society of Cardiology (PASCAR)
First Cardiac Imaging Conference
Sudan Heart Society (SHS) Fourth International Conference

Time	Sunday 31/1/2016
08:30-10:10	General and Preventive Cardiology
Chairpersons	Sajeda Khan Awad Abdallah
08:30 - 08:50	 Anas Albadawi (Sudan) Lipids Lowering. Update.
08:50 - 09:10	 Liesl Zuhlke (South Africa) Diagnosis and long term management of Rheumatic Carditis
09:10 - 09:30	 Amir Zaini (Saudi Arabia) Obesity and the heart
09:30 - 09:50	Magdi Gameel Salt and The Heart
09:50 - 10:10	Discussion
10:10 - 10:40	 Coffee break



Time	Sunday 31/1/2016
10:40-12:40	Acute Coronary Syndrome
Chairpersons	Angela Hoey Omar Abobaker
10:40 - 11:20	 Sajeda Khan (South Africa) Reperfusion Strategy in STEMI.
	 Murtada Halim (Saudi Arabia) Type 2 Myocardial Infarction
11:20 - 11:40	 Anjela Hoye (UK) Cath lab management of NSTEMI
11:40 - 12:00	To be announced
12:00 - 12:20	 Awad Abdallah (Sudan) Management of STEMI in Sudan. Where do we stand.
12:20 - 12:40	Discussion
12:40 - 13:30	 Lunch & Prayers

Time	Sunday 31/1/2016
13:30-15:10	Heart Failure 3
Chairpersons	Karen Sliwa Siddig Ibrahim Khaleel
13:30 - 13:50	 Zaheer Yousof (UK) Prognosis of Heart Failure.. Any progress ?
13:50 - 14:10	 Anders Barasa (Kenya) Novel therapy in HF
14:10 - 14:30	 Zaheer Yousof (UK) Right Heart Failure. Any special approach?
14:30 - 14:50	 Lori West (Canada) Heart Transplant, For whom ?
14:50 - 15:10	Discussion
15:10 - 15:40	 Coffee Break



Sunday 31/1/2016

15:40-17:00

Coronary Artery Disease (2)

Chairpersons

Mohammad Rosli
Murtada Halim

15:40-16:00



Moh. Rosli Malaysia (UK)

History of PCI: The struggle against MACE

16:00-16:20



Anjela Hoye (UK)

Two stents strategies for bifurcation lesions

16:20-16:40



Murtada Halim (Saudi Arabia)

Controversaries in Coronary Interventions

16:40-17:00



Anjela Hoye (UK)

How to do provisional Bifurcation Stenting

16:40-17:00

Discussion

17:00

Farewell
Closing remarks

AMILODIPINE

(AMILODIPINE BESILATE)

The commonly used calcium channel blocker.

Together with diet control and exercise Amilodipine offers the best results in managing :


- Hypertension.
- Angina.
- All other complications of coronary artery disease.
- Can also be used safely in patients with asthma, COPD, diabetes, hyperlipidemia and peripheral vascular disease.



AMILODIPINE

has a high safety profile

In addition to the once daily dosage, the high quality and affordable price boosts patient's compliance enabling clinicians to obtain the maximum patient compliance and disease management reducing mortality and morbidity.



AMILODIPINE offers versatility of dosage available in both concentrations.

5 mg and 10 mg.



AMIPHARMA

Diamond Sponsor



AMIPHARMA

Platinum Sponsor

تبوك
الدوائية المحدودة



tabuk
pharmaceutical Co. Ltd.

Golden Sponsor



NOVARTIS

Silver Sponsor

AstraZeneca



**NATIONAL COMPANY FOR
PHARMACEUTICAL INDUSTRY**



EXPO Developed Projects Co.LTD
شركة اكسيو للمشاريع المتطورة المحدودة



For More Information



Sudan Office

Maamoon Bhiery St | East Afra Center | Arkweet | Khartoum
Tel/Fax: +[249] 123450797 Mobile: +24990 191 1010
Mail: info@expoccg.com | alaa.tarek@expoccg.com | Website : www.expoccg.com



Egypt Office

17 (A) Obour Buldings | Salah Salem Road | Cairo
Tel/Fax: +[202] 24034542 Mobile: +[2] 01117719 / 222 / 444 / 888
Mail: info@ccg-eg.org | Website : www.ccg-eg.org



UAEOffice

UAE - Dubai | Business Bay | Al Manara Tower – Floor 29 | Office 2902
Tel/Fax: + 971 4 321 8987 | + 971 55 9727 666
Mobile: + 971 455 19203 | + 971 455 19216
Mail: yasser.younes@ccg-eg.org | uae@ccg-eg.org | Website : www.ccg-eg.org